Clinical Trial

A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 18, 2023 (before its estimated June 2024 completion). Its status may not reflect the trial's current state.
Summary
This research study will evaluate the efficacy and safety of stereotactic radiotherapy (SRT) combined with Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-positive Breast Cancer Patients with newly diagnosed or progressing Brain Metastases.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT06088056
Lead Sponsor Fudan University
Conditions Breast Cancer, Brain Metastases, Radiotherapy
Enrollment 17 participants
Start Date 2023-11
Primary Completion 2024-06 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2023-10-18